Pacer Advisors Inc. Cuts Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)

Key Points

• Pacer Advisors Inc. reduced its stake in USANA Health Sciences by 78.5%, selling 464,507 shares to now hold approximately 0.68% of the company.
• USANA's stock has seen a performance dip, trading at $30.29, with a recent earnings report showing EPS of $0.74, exceeding analyst expectations of $0.54.
• Several hedge funds have increased their positions in USANA, with Versant Capital Management boosting holdings by 542.5% in the first quarter.

Pacer Advisors Inc. cut its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 78.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,494 shares of the company's stock after selling 464,507 shares during the quarter. Pacer Advisors Inc. owned about 0.68% of USANA Health Sciences worth $3,439,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Exchange Traded Concepts LLC grew its position in shares of USANA Health Sciences by 7.1% in the first quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock valued at $248,000 after purchasing an additional 606 shares in the last quarter. Versant Capital Management Inc grew its position in shares of USANA Health Sciences by 542.5% in the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock valued at $31,000 after purchasing an additional 971 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of USANA Health Sciences by 15.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,234 shares of the company's stock valued at $260,000 after purchasing an additional 985 shares in the last quarter. Franklin Resources Inc. grew its position in shares of USANA Health Sciences by 4.8% in the fourth quarter. Franklin Resources Inc. now owns 22,070 shares of the company's stock valued at $792,000 after purchasing an additional 1,020 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in shares of USANA Health Sciences by 8,141.2% in the first quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock valued at $38,000 after purchasing an additional 1,384 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider David Mulham Mulham sold 3,515 shares of the business's stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the transaction, the insider directly owned 9,260 shares in the company, valued at $280,207.60. The trade was a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Walter Noot sold 6,291 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total value of $190,554.39. The disclosure for this sale can be found here. Insiders sold a total of 15,528 shares of company stock worth $466,513 over the last ninety days. 0.63% of the stock is owned by corporate insiders.

USANA Health Sciences Trading Down 1.7%

Shares of NYSE USNA traded down $0.49 during mid-day trading on Friday, hitting $28.91. The company had a trading volume of 54,746 shares, compared to its average volume of 183,492. USANA Health Sciences, Inc. has a 1 year low of $23.10 and a 1 year high of $43.26. The stock's 50-day moving average price is $30.91 and its 200-day moving average price is $29.97. The company has a market capitalization of $538.30 million, a price-to-earnings ratio of 16.06, a P/E/G ratio of 0.94 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.54 by $0.20. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. The business had revenue of $235.85 million during the quarter, compared to analysts' expectations of $225.20 million. As a group, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.